Platelet-rich plasma (PRP): A new therapy for erectile dysfunction

Background: Erectile dysfunction (ED) is a common condition with multifactorial causes, affecting men's quality of life and mental health. Traditional treatments like PDE5 inhibitors and penile implants provide symptomatic relief but do not address the underlying pathology. Recent advances in regenerative medicine have introduced platelet-rich plasma (PRP) as a potential therapy for ED. The rich in growth factors, PRP promotes tissue regeneration, angiogenesis, and endothelial repair. Preclinical and clinical studies suggest PRP may improve erectile function by enhancing penile blood flow and vascular integrity. Aim of the study: The aim of this study was to assess the effectiveness of platelet-rich plasma (PRP) as a treatment for erectile dysfunction (ED) by evaluating its impact on erectile function over time based on sexual function scores. Methods: This prospective observational study was conducted on 45 male patients (40-70 years) diagnosed with erectile dysfunction (ED) at Ajoy Joba Shebasram and R. (Private Chamber), Jorakol Bazar, khulna, Bangladesh from January to December 2024. Baseline assessments included demographic, clinical, and metabolic parameters. Participants received structured treatment (lifestyle modifications, pharmacotherapy, or both), with sexual function assessed using the International Index of Erectile Function (IIEF) at baseline and follow-ups (1st, 3rd, and 6th months). Platelet-rich plasma (PRP) was prepared via centrifugation and injected into the corpus cavernosum. Data were analyzed using SPSS v26, with repeated measures of ANOVA assessing IIEF score changes. A p-value